The FDA is encouraging sponsors of drugs indicated to treat hypertension to cite cardiovascular outcome claims in promotional materials, in a final guidance issued Dec. 16. The guidance – Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims – recommends reproduction of the entire indications and usage section. However, the guidance adds that a minimum desc... Read More